Replies to post #8827 on Biotech Values

[DewDiligence]

Re: CFH gene for AMD

The majority of drugs and drug candidates for AMD are targeting VEGF. This does not mean that VEGF is the best target to target, only that VEGF is the best validated target to target.

In the minds of drug-development companies, VEGF officially became validated when Avastin showed a survival benefit in colorectal cancer,

It will probably be several years before an AMD drug candidate emerges for the CFH gene. For investors in such companies as GENR, EYET, ALNY, and GNVC, this is a development to watch but not one to worry about unduly.

[DewDiligence]

ParAllele BioScience, Inc. and University of Iowa Collaborate to Discover Genes Responsible for Macular Degeneration

http://biz.yahoo.com/prnews/050328/sfm095.html?.v=4

>>
SOUTH SAN FRANCISCO, Calif., March 28 /PRNewswire/ -- ParAllele BioScience, Inc. announced today its joint collaboration agreement with the University of Iowa Cell Biology and Functional Genomics Laboratory, the UI Department of Ophthalmology and Visual Sciences and the UI Center for Macular Degeneration to accelerate the discovery of genes associated with age-related macular degeneration (AMD). The research initiative will be led by Gregory Hageman, Ph.D., professor at the UI Carver College of Medicine.

AMD is the leading cause of irreversible vision loss in the developed world, affecting 15 to 20 percent of individuals over the age of 60, or an estimated 50 million individuals.

"The molecular events leading to the development of AMD are poorly understood and no pharmacological treatment has been shown to be effective in preventing, arresting or reversing the loss of vision associated with early AMD," Hageman said.

Recent genome-wide linkage analyses have revealed loci on multiple chromosomes with the potential to harbor major AMD-associated genes. "We choose to collaborate with ParAllele because of their ability to comprehensively analyze those regions for both common and rare mutations that may be AMD-associated," he added. "Our long range goal is to identify new pathways and therapeutic targets that will hasten the development of pharmaceutical agents capable of delaying the onset and/or progression of AMD."

Hageman's studies are funded by the National Eye Institute at NIH and additional corporate entities.

"The agreement is an exciting opportunity for us to combine ParAllele's strengths in pharmacogenomics and high throughput gene mutation discovery with the acknowledged leadership of Dr. Hageman and his Institute in the field of AMD-associated pathways," said Nick Naclerio, CEO of ParAllele BioScience, Inc.

About ParAllele BioScience

ParAllele BioScience, Inc. is accelerating healthcare breakthroughs by providing comprehensive genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The understanding of how subtle genetic variations contribute to disease risk, prognosis and drug response will lead to new and more effective drugs, predictive diagnosis, and the ability to better tailor therapies to individual patients. Headquartered in South San Francisco, California, ParAllele BioScience was founded by a team of leading researchers from the Stanford Genome Technology Center and Uppsala University. The company's investors include Abingworth Management, Index Ventures, Mohr Davidow Ventures, and Versant Ventures. For more information about ParAllele, please visit the company's website at: www.parallelebio.com.
<<